Select a Region North America

Innovation for Rare & Orphan Drugs

Advancing the Commercialization of Rare & Orphan Drugs

Innovative Therapies Deserve Innovative Strategies

With more than 7,000 distinct types of rare and genetic diseases and 400+ million individuals suffering from a rare disease, regenerative medicine holds the hope for a cure – transforming healthcare by revolutionizing patient care from conventional treatment models to curative therapy models. With the advancement of new technologies coupled with the creation of new companies offering a range of innovative products and treatments, regenerative medicine constitutes one of the fastest-growing fields of research and the promise of commercial success for all patients.

Creating better patient experiences and bringing effective therapies to patients around the world

In the value-driven healthcare environment, rare and orphan drug manufacturers are becoming increasingly aware that new models and new approaches are needed for a successful product launch. At EVERSANA, we understand the complexities of developing products for small populations that require global reach. That’s why we are focused on an end-to-end process that’s connected and assures that patients are identified, diagnosed and onboarded and that they stay adherent to their therapies.

Patient Services Operational Excellence | Patient Support Hub | Rare Disease



Top Issues We Address

  • Upcoming innovative changes in research, clinical development, manufacturing, registrational paths and commercial models impacting the rare disease community
  • Developing strong economic models in demonstrating the value of subsidizing patient healthcare costs
  • Finding the right patients and designing a collaborative clinical trial
  • Establishing a well-informed sales and marketing plan
  • Accurate forecasting to ensure successful market access
  • Optimizing a supply chain management system

Digital Guide to Commercializing Complex Therapies

This user-friendly digital guide aims to assist in navigating the challenges associated with commercializing complex therapiesEffortlessly jump from section to section based on your areas of interest. As is the case with all EVERSANA capabilities, the guide is flexible and customizable based on your unique needs.

Click here to access the full guide.

Leveraging AI to Advance Rare Disease Patient Identification and Commercialization

Today we have access to more data from more sources than we could ever dream possible. The need for data is elevated as diagnosis becomes a race against time and the pipeline for innovative new therapies continues to grow. In 2019, the FDA approved 22 drugs and biologics with orphan drug designation. In 2020, they approved 31. As this pipeline expands, manufacturers have a responsibility to the patient to ask themselves – How do we cut down that time to diagnosis?

Delays in rare disease diagnosis can be an understandable result of provider expertise. Providers may see one or two rare cases in a year — or in a career, which is not enough to refer to or look for diagnostic criteria to find patients who may be hiding in HIPAA-compliant data.

Harness the Power of Data

With machine learning that enables the synthesis of disparate data sets to provide greater insight into the patient journey and the disease progression, manufacturers can help bridge the gap between data aggregation and execution. When manufacturers leverage RWD to generate RWE (from electronic medical records, claims, physician and nonclinical data, etc.), they can inform the start of the patient journey – not just the end. From this, a data-driven pull-through for patient care will be possible. With the power of aggregated data, manufacturers can give providers the data they need for a broader, more efficient diagnosis experience.

Accelerating Rare Disease Patient Engagement

Read EVERSANA INTOUCH's latest insights that empower and support brands in identifying, engaging with, and treating rare patients at an ever-increasing speed to stay competitive.

Featured Content

Critical Success Factors for Launching Products with Orphan Drug Designation

The Orphan Drug Act (ODA) was passed in 1983 to financially incentivize pharmaceutical companies to develop drugs for rare diseases or conditions, defined as a disease or condition that affects less than 200,000 people in the US.1 The financial incentives offered by the ODA are substantial and include tax credits up to 50% of the […]

The IDeaS Initiative: Pilot Study to Assess the Impact of Rare Diseases on Patients and Healthcare Systems

When combined, rare diseases (RD) are not actually rare, as they collectively affect around 25–30 million people in the United States (US) and more than 300 million people worldwide. RD represent a diverse spectrum of more than 7–10,000 different disorders, most of which affect only a few hundred to a few thousand people per disease. […]

Explore Our Services

  • EVERSANA COMPLETE Commercialization

    A new model, purposefully built to act as your commercialization engine.

    자세히 알아보기
  • Clinical & Commercial Teams

    With one focused and unified voice, we deploy commercial teams to propel your brand in active, vacant and white space territories.

    자세히 알아보기
  • Market Access & Reimbursement

    A partner you can trust to navigate today’s complex landscape

    자세히 알아보기

    The premier tech-enabled solution built to deliver end-to-end commercial success for life sciences companies

    자세히 알아보기


Contact us to learn more about our capabilities